Jan. 7 at 6:41 PM
Oramed Pharmaceuticals announced it received an
$18 million payment from Scilex Holdings, fully satisfying obligations under their Option Agreement. The payment brings Oramed’s total returns to
$118 million on its original
$99.5 million investment in Scilex, with additional potential upside from remaining financial instruments.
Oramed still holds a
$27 million note and a
$12 million convertible note, which can be converted into Scilex shares at
$36 per share or repaid in quarterly installments through October 2026 if not converted. The company also retains warrants and a nine-year royalty interest in Scilex products, offering further potential returns.
Alongside the payment, Oramed’s board approved a
$0.25 per share cash dividend, with an ex-dividend date of January 16, 2026, and payment scheduled for January 26, 2026. The dividend, totaling about
$10.5 million, will be funded from excess capital and reflects a direct return of value to shareholders.
$ORMP $SCLX